Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Summary

The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).

Timeline

Start

2018-01-12

Primary completion

2025-03-31

Completion

2025-03-31

Outcome

Missed primary endpoint

registry analysis (superiority test); Avacincaptad Pegol vs Sham; p = 0.8669; difference in LS mean -0.0261 (95% CI -0.3334 to 0.2813); Mixed Models Analysis NCT03364153 ↗

Drugs

Indications